1. Home
  2. TSHA vs EFC Comparison

TSHA vs EFC Comparison

Compare TSHA & EFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSHA
  • EFC
  • Stock Information
  • Founded
  • TSHA 2019
  • EFC 2007
  • Country
  • TSHA United States
  • EFC United States
  • Employees
  • TSHA N/A
  • EFC 400
  • Industry
  • TSHA Biotechnology: Pharmaceutical Preparations
  • EFC Real Estate
  • Sector
  • TSHA Health Care
  • EFC Finance
  • Exchange
  • TSHA Nasdaq
  • EFC Nasdaq
  • Market Cap
  • TSHA 1.4B
  • EFC 1.5B
  • IPO Year
  • TSHA 2020
  • EFC 2010
  • Fundamental
  • Price
  • TSHA $3.84
  • EFC $13.36
  • Analyst Decision
  • TSHA Strong Buy
  • EFC Strong Buy
  • Analyst Count
  • TSHA 9
  • EFC 7
  • Target Price
  • TSHA $10.22
  • EFC $14.46
  • AVG Volume (30 Days)
  • TSHA 4.1M
  • EFC 1.2M
  • Earning Date
  • TSHA 11-04-2025
  • EFC 11-05-2025
  • Dividend Yield
  • TSHA N/A
  • EFC 11.69%
  • EPS Growth
  • TSHA N/A
  • EFC 1.24
  • EPS
  • TSHA N/A
  • EFC 1.33
  • Revenue
  • TSHA $6,310,000.00
  • EFC $328,650,000.00
  • Revenue This Year
  • TSHA N/A
  • EFC N/A
  • Revenue Next Year
  • TSHA N/A
  • EFC $8.81
  • P/E Ratio
  • TSHA N/A
  • EFC $10.02
  • Revenue Growth
  • TSHA N/A
  • EFC 13.55
  • 52 Week Low
  • TSHA $1.05
  • EFC $11.12
  • 52 Week High
  • TSHA $5.51
  • EFC $14.40
  • Technical
  • Relative Strength Index (RSI)
  • TSHA 37.78
  • EFC 46.30
  • Support Level
  • TSHA $3.89
  • EFC $13.10
  • Resistance Level
  • TSHA $4.55
  • EFC $14.04
  • Average True Range (ATR)
  • TSHA 0.39
  • EFC 0.25
  • MACD
  • TSHA -0.19
  • EFC 0.01
  • Stochastic Oscillator
  • TSHA 8.99
  • EFC 27.77

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

About EFC Ellington Financial Inc.

Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.

Share on Social Networks: